Yan Audrey, Jones Crandall, Demirel Sibel, Chhablani Jay
Department of Medicine, West Virginia School of Osteopathic Medicine, Lewisburg, WV, USA.
Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Graefes Arch Clin Exp Ophthalmol. 2025 Feb;263(2):249-258. doi: 10.1007/s00417-024-06595-7. Epub 2024 Jul 29.
Diabetic macular edema (DME) is a serious vision-threatening complication that can arise at any stage of diabetic retinopathy. Primary treatment involves anti-vascular endothelial growth factor (VEGF) agents, which are highly effective but associated with challenges, such as the need for frequent injections, relapses, and resistance to therapy. Therefore, there has been a growing interest in developing new treatments that offer similar or superior outcomes in DME. This review article explores emerging treatments, including WNT agonists, gene therapy, protein inhibitors, and, most importantly, the first-ever non-invasive and oral drugs. The evolving therapies in diabetic retinopathy offer hope for continued improvement in vision loss associated with one of the most common chronic conditions worldwide.
糖尿病性黄斑水肿（DME）是一种严重的视力威胁性并发症，可在糖尿病视网膜病变的任何阶段出现。主要治疗方法包括抗血管内皮生长因子（VEGF）药物，这些药物非常有效，但也伴随着一些挑战，如需要频繁注射、复发以及对治疗产生耐药性。因此，人们越来越有兴趣开发在DME治疗中能提供相似或更好疗效的新疗法。这篇综述文章探讨了新兴的治疗方法，包括WNT激动剂、基因治疗、蛋白抑制剂，最重要的是，首次出现的非侵入性口服药物。糖尿病视网膜病变不断发展的治疗方法为改善与全球最常见慢性病之一相关的视力丧失带来了希望。
